Mild Cognitive ImpairmentLIFUP-MCIADNCT05417555
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
A study testing Low-Intensity Focused Ultrasound Pulsation (LIFUP) in people with Mild Cognitive Impairment and Amnestic Mild Cognitive Disorder, run by University of California, Los Angeles at 1 site in United States.
Trial summary
The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild Cognitive Impairment and Mild Alzheimer's Disease. Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Deep Brain Stimulation
- What is being tested?
- Low-Intensity Focused Ultrasound Pulsation (LIFUP)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2022to 15 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Amnestic MCI or Mild Alzheimer's diagnosis
- Age 50-90
- English-speaking
- Ability to provide informed consent
- Normal or corrected-to-normal hearing and vision
Who cannot join
- GENERAL
- Participation in another clinical trial
- Active use of immunotherapeutic medications for cognition (Aduhelm, Leqembi, Kisunla)
- Moderate to Severe Alzheimer's
- Inability to provide informed consent
- MRI-Related:
Show all 32Show fewer
- Weight exceeding 275 pounds
- Pregnancy, suspicion of pregnancy, or attempting to become pregnant
- Claustrophobia
- Difficulties during previous MRIs
- Top permanent retainer (bottom only is okay), 5 or more non-removable gold-teeth, metal braces, top spacers, and/or palate expanders
- Any of the following implants: Cardiac Pacemaker, Aneurysm clips, Cochlear implants, Defibrillator, Electrodes or wires, Magnetically-activated device, Spinal cord stimulator, Infusion or insulin pumps, Implanted drug infusion device, Deep brain stimulation device
- Non-removable hairpieces, hairpiece extensions, and/or piercings
- Facial tattoos or permanent makeup
- Metal implants that are MR-incompatible, or where participant is unable to provide sufficient information to determine MR compatibility
- Previous injury by metallic foreign body (e.g., bullet, BB, shrapnel) where the object entered the body and participant lacks doctor's confirmation that it was fully removed
- Medical:
- Diagnosis of one or more of the following neurological disorders: Parkinson's disease, Lou Gehrig's disease (ALS), Multiple sclerosis, Cerebral Palsy
- Diagnosis of one or more of the following genetic disorders: Cystic Fibrosis, Sickle Cell Disease
- Diagnosis of one or more of the following psychiatric disorders: Bipolar, Psychosis
- Psychiatric illness that has not been controlled for at least two months (if controlled >2 months, with or without medication, they are not exclusionary)
- Severe lung, liver, heart, and/or kidney disease/s (e.g., heart failure, liver failure, and etc...)
- Diagnosis of thyroid disorder or change of thyroid medication dose within the last 3 months
- Cancer treatment/s with chemotherapy and/or radiation to head and neck, or stage 4 (metastatic) cancer
- Autoimmune disorder or viral infection such as HIV, COVID 19, or hepatitis C that has caused current problems with cognition/memory
- History of substance abuse in the past year
- History of stroke (Transient ischemic attack / mini-stroke not exclusionary if symptoms lasted <1 week)
- History of 2 or more seizures or diagnosis of epilepsy, unless the seizures occurred prior to age 5 alongside a fever.
- History of brain tumor, brain aneurysm, brain hemorrhage, or subdural hematoma (transient ischemic attack not exclusionary)
- Head injury that resulted in loss of consciousness lasting >30 minutes, cognitive issues lasting >18 months, and/or brain abnormalities visible in CT or MRI scan
- Uncontrolled high blood pressure or diabetes
- Heart attack within the last year
Trial locations and contacts
1 site in 1 country.
United States1 site
UCLA Semel Institute for Neuroscience and Behavior
Los Angeles, California, 90024
About this study
Official title: Modulation of Hippocampal Circuitry and Memory Function With Focused Ultrasound in Amnestic MCI
The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild Cognitive Impairment and Mild Alzheimer's Disease.
The main questions the study seeks to answer are:
- Can LIFUP increase brain activity in the targeted area?
- Can LIFUP improve memory in people with MCI and mild AD?
- Can LIFUP improve connectivity of memory networks in the brain?
Participants in this study will complete MRIs and memory testing, and receive Low Intensity Focused Ultrasound to a part of their brain involved in memory (the entorhinal cortex).
Read the detailed description
This is a proof of concept trial of Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting the entorhinal cortex in patients with amnestic MCI and Mild Alzheimer's Disease. Participation in the study will entail one Zoom intake session, three in-person sessions and three remote Zoom follow-up sessions over the course of about five weeks. The in-person sessions will take about 5 hours for the first and 3 hours for the following two. The Zoom intake session will take 1-2 hours, and the Zoom follow-up sessions will take about 2 hours each. Participants will be asked to complete questionnaires and tests of learning and memory, have their blood drawn, undergo painless ultrasound stimulation to a part of their brain related to memory, and complete MRI scans of their brain. LIFUP will be administered inside of the MRI scanner, so that we can measure changes in brain activity in real-time.
At the start of the study, you will be randomly assigned to one of four different groups that determines the amount of LIFUP stimulation you will receive. You have an equal chance of being assigned to each group. Participants in one of the three active stimulation groups will receive either 1 dose, 2 doses, or 3 doses of LIFUP at their second in-person session, and will receive the same dose again at their third in-person session. Participants in the placebo group will receive no LIFUP stimulation at either MRI/LIFUP session (in-person visits 2 and 3). However, if at the end of our study, the treatment has been shown to be effective, and you were a placebo subject, we will offer you a free session using the most effective dose.
- Conditions
- Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Deep Brain Stimulation, Mild Alzheimer's Disease
- Being tested
- Low-Intensity Focused Ultrasound Pulsation (LIFUP)
- Keywords
- deep brain stimulation (DBS), transcranial focused ultrasound stimulation (tFUS), memory, low-intensity focused ultrasound pulsation (LIFUP), fMRI, mild cognitive impairment, mci, noninvasive brain stimulation (NIBS), ultrasound, Alzheimer's Disease, Mild Alzheimer's
- Medical subject headings
- Cognitive Dysfunction, Neurocognitive Disorders, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-Intensity Focused Ultrasound Pulsation (LIFUP)Device
Also called transcranial focused ultrasound, tFUS, LIFUP, low intensity focused ultrasound
Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
| Study group | Role | What they receive |
|---|---|---|
| LIFUP Dose Group 1 | Active comparator | Administration of low intensity focused ultrasound (LIFUP) dose level 1 to the entorhinal cortex. Receives: Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP) |
| LIFUP Dose Group 2 | Active comparator | Administration of low intensity focused ultrasound (LIFUP) dose level 2 to the entorhinal cortex. Receives: Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP) |
| LIFUP Dose Group 3 | Active comparator | Administration of low intensity focused ultrasound (LIFUP) dose level 3 to the entorhinal cortex. Receives: Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP) |
| Sham LIFUP | Sham comparator | No administration of LIFUP. The device will be affixed to the user's head but not turned on.
Additionally, if at the end of the study, the treatment has been shown to be effective, placebo subjects will be offered a free session using the optimally effective dose, if they consented to being contacted for this purpose. Receives: Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Perfusion Arterial Spin Labeling (ASL) fMRI Signal throughout Brain
Perfusion ASL fMRI data will be collected before and after sonication. Analyses will assess the statistical relationship between ASL signal throughout the brain pre and post sonication.
Measured: 40 minutes
Changes in BOLD-related functional connectivity from baseline in fMRI brain scan to 40 minutes.
Primary outcomes for proof of mechanism that may be depicted in the fMRI scans may include changes in BOLD-related functional connectivity increases within the DMN including regions functionally connected to the target.
BOLD data will be collected before, during, and following LIFUP sonication. Analyses will assess any changes in BOLD signal in the brain following sonication.
Measured: 40 minutes
Secondary outcomes (5)
Change in Brief Visual Memory Test Scores
Potential LIFUP-related changes in memory will be assessed via neuropsychological assessments including the Brief Visual Memory Tests (BVMT). Scores range from 0 to 12 and reflect recent, long-term learning, with higher scores indicating better learning.
Measured: 48 hours
Change in Verbal Learning Test Scores
Potential LIFUP-related changes in memory will be assessed via the Rey Auditory Verbal Learning Test (RAVLT) neuropsychological assessment. The RAVLT involves providing participants with 15 unrelated words and asking them to recall the word list. There are 5 trials designed to determine short-term memory and then a 20 minute delay to assess long-term memory. The total words correct in both the short- and long-term trials are used as outcome measures.
Measured: 48 hours
Post-hoc biomarker analysis of APOE-4 status as a predictor of tFUS efficacy
Biomarker post hoc analysis will determine the degree to which blood based biomarkers predict the level of effectiveness of tFUS. Samples are collected before LIFUP is administered.
Measured: Baseline (pre-LIFUP)
Post-hoc biomarker analysis of plasma AB42/40 ratio as a predictor of tFUS efficacy
Biomarker post hoc analysis will determine the degree to which blood based biomarkers predict the level of effectiveness of tFUS. Samples are collected before LIFUP is administered.
An Aβ42/40 ratio <0.160 suggests a higher-than-normal risk of having of AD and is warranted to support a diagnosis of AD (West et al 2021).
Measured: Baseline (pre-LIFUP)
Post-hoc biomarker analysis of plasma ptau as a predictor of tFUS efficacy
Biomarker post hoc analysis will determine the degree to which blood based biomarkers predict the level of effectiveness of tFUS. Samples are collected before LIFUP is administered.
Measured: Baseline (pre-LIFUP)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2022
- Study start1 Sep 2022
- Primary completion15 Sep 2026 (estimated)
- Study completion15 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Subjects are randomly assigned to one of four treatment dosage conditions: 0, 1, 2 or 3 treatments at each MRI-LIFUP session. After 2 weeks, a second dose is administered with the same dosage level for each subject. Memory assessment occurs once at baseline and remotely after each treatment at the onset of the optimal time window (48 hours) for LIFUP-induced change based on prior data. Finally, after 2 weeks, memory is again assessed. Alternate forms are used for the primary outcome measures to avoid practice effects.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Principal investigator, Susan Bookheimer, PhD, University of California, Los Angeles
- Investigators
- Susan Y Bookheimer, PhD, Principal investigator, UCLA Psychiatry & Biobehavioral Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05417555
- Sponsor's protocol ID
- IRB#21-000995
- Other IDs
- 1R01AG073480-01, IRB#21-000995
- Acronym
- LIFUP-MCIAD
- Status last verified
- Dec 2025
- First submitted
- 1 Jun 2022
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Hescham S, Lim LW, Jahanshahi A, Blokland A, Temel Y. Deep brain stimulation in dementia-related disorders. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2666-75. doi: 10.1016/j.neubiorev.2013.09.002. Epub 2013 Sep 20.
PubMed 24060532Lin WT, Chen RC, Lu WW, Liu SH, Yang FY. Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. Sci Rep. 2015 Apr 15;5:9671. doi: 10.1038/srep09671.
PubMed 25873429Burgess A, Dubey S, Yeung S, Hough O, Eterman N, Aubert I, Hynynen K. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology. 2014 Dec;273(3):736-45. doi: 10.1148/radiol.14140245. Epub 2014 Sep 15.
PubMed 25222068Bystritsky A, Korb AS, Douglas PK, Cohen MS, Melega WP, Mulgaonkar AP, DeSalles A, Min BK, Yoo SS. A review of low-intensity focused ultrasound pulsation. Brain Stimul. 2011 Jul;4(3):125-36. doi: 10.1016/j.brs.2011.03.007. Epub 2011 Apr 1.
PubMed 21777872
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modulation of Hippocampal Circuitry and Memory Function With Focused Ultrasound in Amnestic MCI
- ClinicalTrials.gov ID
- NCT05417555
- Acronym / sponsor ID
- LIFUP-MCIAD / IRB#21-000995
- Conditions
- Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Deep Brain Stimulation, Mild Alzheimer's Disease
- Keywords
- deep brain stimulation (DBS), transcranial focused ultrasound stimulation (tFUS), memory, low-intensity focused ultrasound pulsation (LIFUP), fMRI, mild cognitive impairment, mci, noninvasive brain stimulation (NIBS)
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 120 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 15 Sep 2026 (estimated)
- Study completion
- 15 Sep 2026 (estimated)
- First posted
- 14 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild Cognitive Impairment and Mild Alzheimer's Disease.
The main questions the study seeks to answer are:
- Can LIFUP increase brain activity in the targeted area?
- Can LIFUP improve memory in people with MCI and mild AD?
- Can LIFUP improve connectivity of memory networks in the brain?
Participants in this study will complete MRIs and memory testing, and receive Low Intensity Focused Ultrasound to a part of their brain involved in memory (the entorhinal cortex).
Detailed description
This is a proof of concept trial of Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting the entorhinal cortex in patients with amnestic MCI and Mild Alzheimer's Disease. Participation in the study will entail one Zoom intake session, three in-person sessions and three remote Zoom follow-up sessions over the course of about five weeks. The in-person sessions will take about 5 hours for the first and 3 hours for the following two. The Zoom intake session will take 1-2 hours, and the Zoom follow-up sessions will take about 2 hours each. Participants will be asked to complete questionnaires and tests of learning and memory, have their blood drawn, undergo painless ultrasound stimulation to a part of their brain related to memory, and complete MRI scans of their brain. LIFUP will be administered inside of the MRI scanner, so that we can measure changes in brain activity in real-time.
At the start of the study, you will be randomly assigned to one of four different groups that determines the amount of LIFUP stimulation you will receive. You have an equal chance of being assigned to each group. Participants in one of the three active stimulation groups will receive either 1 dose, 2 doses, or 3 doses of LIFUP at their second in-person session, and will receive the same dose again at their third in-person session. Participants in the placebo group will receive no LIFUP stimulation at either MRI/LIFUP session (in-person visits 2 and 3). However, if at the end of our study, the treatment has been shown to be effective, and you were a placebo subject, we will offer you a free session using the most effective dose.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 4
- Model description
- Subjects are randomly assigned to one of four treatment dosage conditions: 0, 1, 2 or 3 treatments at each MRI-LIFUP session. After 2 weeks, a second dose is administered with the same dosage level for each subject. Memory assessment occurs once at baseline and remotely after each treatment at the onset of the optimal time window (48 hours) for LIFUP-induced change based on prior data. Finally, after 2 weeks, memory is again assessed. Alternate forms are used for the primary outcome measures to avoid practice effects.
| Arm | Type | Receives |
|---|---|---|
| LIFUP Dose Group 1 | Active comparator | Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP)Administration of low intensity focused ultrasound (LIFUP) dose level 1 to the entorhinal cortex. |
| LIFUP Dose Group 2 | Active comparator | Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP)Administration of low intensity focused ultrasound (LIFUP) dose level 2 to the entorhinal cortex. |
| LIFUP Dose Group 3 | Active comparator | Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP)Administration of low intensity focused ultrasound (LIFUP) dose level 3 to the entorhinal cortex. |
| Sham LIFUP | Sham comparator | Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP)No administration of LIFUP. The device will be affixed to the user's head but not turned on. Additionally, if at the end of the study, the treatment has been shown to be effective, placebo subjects will be offered a free session using the optimally effective dose, if they consented to being contacted for this purpose. |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Amnestic MCI or Mild Alzheimer's diagnosis
- Age 50-90
- English-speaking
- Ability to provide informed consent
- Normal or corrected-to-normal hearing and vision
Key exclusion criteria (32 listed)
- GENERAL
- Participation in another clinical trial
- Active use of immunotherapeutic medications for cognition (Aduhelm, Leqembi, Kisunla)
- Moderate to Severe Alzheimer's
- Inability to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low-Intensity Focused Ultrasound Pulsation (LIFUP)Also: transcranial focused ultrasound, tFUS, LIFUP, low intensity focused ultrasoundLow intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment) | Device | LIFUP Dose Group 1, LIFUP Dose Group 2, LIFUP Dose Group 3, Sham LIFUP |
Primary outcome
Change in Perfusion Arterial Spin Labeling (ASL) fMRI Signal throughout Brain
Time frame: 40 minutes
Perfusion ASL fMRI data will be collected before and after sonication. Analyses will assess the statistical relationship between ASL signal throughout the brain pre and post sonication.
Changes in BOLD-related functional connectivity from baseline in fMRI brain scan to 40 minutes.
Time frame: 40 minutes
Primary outcomes for proof of mechanism that may be depicted in the fMRI scans may include changes in BOLD-related functional connectivity increases within the DMN including regions functionally connected to the target. BOLD data will be collected before, during, and following LIFUP sonication. Analyses will assess any changes in BOLD signal in the brain following sonication.
5 secondary outcomes
Change in Brief Visual Memory Test Scores
Time frame: 48 hours
Change in Verbal Learning Test Scores
Time frame: 48 hours
Post-hoc biomarker analysis of APOE-4 status as a predictor of tFUS efficacy
Time frame: Baseline (pre-LIFUP)
Post-hoc biomarker analysis of plasma AB42/40 ratio as a predictor of tFUS efficacy
Time frame: Baseline (pre-LIFUP)
Post-hoc biomarker analysis of plasma ptau as a predictor of tFUS efficacy
Time frame: Baseline (pre-LIFUP)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Background: PubMed 24060532Hescham S, Lim LW, Jahanshahi A, Blokland A, Temel Y. Deep brain stimulation in dementia-related disorders. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2666-75. doi: 10.1016/j.neubiorev.2013.09.002. Epub 2013 Sep 20.
- Background: PubMed 25873429Lin WT, Chen RC, Lu WW, Liu SH, Yang FY. Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. Sci Rep. 2015 Apr 15;5:9671. doi: 10.1038/srep09671.
- Background: PubMed 25222068Burgess A, Dubey S, Yeung S, Hough O, Eterman N, Aubert I, Hynynen K. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology. 2014 Dec;273(3):736-45. doi: 10.1148/radiol.14140245. Epub 2014 Sep 15.
- Background: PubMed 21777872Bystritsky A, Korb AS, Douglas PK, Cohen MS, Melega WP, Mulgaonkar AP, DeSalles A, Min BK, Yoo SS. A review of low-intensity focused ultrasound pulsation. Brain Stimul. 2011 Jul;4(3):125-36. doi: 10.1016/j.brs.2011.03.007. Epub 2011 Apr 1.
- Study WebsiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Mild Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susan Y Bookheimer, PhD principal investigator
UCLA Psychiatry & Biobehavioral Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low-Intensity Focused Ultrasound Pulsation (LIFUP) in people with Mild Cognitive Impairment and Amnestic Mild Cognitive Disorder, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Perfusion Arterial Spin Labeling (ASL) fMRI Signal throughout Brain (time frame: 40 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05417555, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.